Rapid Medical Announces FDA Clearance of TIGERTRIEVER 25 for Stroke Treatment

New clot retrieval device designed to address large vessel occlusions demonstrates first-pass success in initial U.S. cases.

Apr. 17, 2026 at 6:50am

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray-style image revealing the intricate, tangled structure of a blood clot, conveying the complex nature of the medical challenge addressed by the new TIGERTRIEVER 25 device.A novel clot retrieval device aims to simplify the pathway to first-pass success in treating the most challenging large vessel occlusions.Southlake Today

Rapid Medical, a developer of active endovascular devices, has announced FDA clearance of its TIGERTRIEVER 25 clot retrieval device for treating large vessel occlusion (LVO) strokes. The TIGERTRIEVER 25 is the largest thrombectomy device on the market, engineered to address occlusions in proximal vessels like the internal carotid artery and M1 segment. Initial U.S. cases have shown the device's ability to achieve first-pass complete reperfusion, a key outcome for improving patient results in stroke intervention.

Why it matters

Acute ischemic stroke remains a leading cause of disability, and effective mechanical thrombectomy devices are critical for restoring blood flow and minimizing long-term damage. The TIGERTRIEVER 25's unique design features, including extended capture length and operator-controlled expansion, aim to improve outcomes for the most challenging LVO cases that conventional devices have struggled with.

The details

The TIGERTRIEVER 25 combines a 53 mm capture length with Rapid Medical's proprietary real-time force control technology, enabling physicians to actively manage clot interaction during the procedure. This adaptability is designed to address long thrombi and stenotic vessels where other devices have limitations. Initial U.S. cases have demonstrated the device's ability to conform to vessel anatomy and effectively engage across long clot segments, potentially reducing complications like clot fragmentation and distal embolization.

  • The TIGERTRIEVER 25 received FDA clearance in April 2026.
  • The first U.S. clinical cases using the TIGERTRIEVER 25 were performed in April 2026.

The players

Rapid Medical

A leading developer of active endovascular devices for ischemic and hemorrhagic stroke treatment.

TIGERTRIEVER 25

Rapid Medical's latest addition to its TIGERTRIEVER platform, designed as the largest thrombectomy device on the market to address large vessel occlusions.

Edgar Samaniego, MD, MS

A physician at the University of Iowa who performed the first U.S. case using the TIGERTRIEVER 25.

Demetrius Lopes, MD

A physician at Advocate Health Care who commented on the versatility and potential of the TIGERTRIEVER 25 device.

Got photos? Submit your photos here. ›

What they’re saying

“With every thrombectomy, we aim at our first pass being the last. The TIGERTRIEVER 25 demonstrated excellent conformability to the vessel anatomy, accommodating the MCA diameter with a smooth transition into the terminal ICA. This adaptability allows for effective engagement across long segments and makes it particularly valuable in large vessel occlusions with high clot burden, even in challenging, angulated anatomy.”

— Edgar Samaniego, MD, MS, University of Iowa

“Acute ischemic stroke intervention today demands a diverse and adaptable toolkit to effectively address the wide spectrum of anatomical and clinical scenarios we encounter, and I am very impressed with the versatility of the TIGERTRIEVER 25 device. Its design streamlines the procedural approach and has the potential to simplify the pathway to achieving first-pass success—an outcome that remains critical for improving patient outcomes in mechanical thrombectomy.”

— Demetrius Lopes, MD, Advocate Health Care

What’s next

Rapid Medical plans to continue expanding the TIGERTRIEVER platform to address the full spectrum of stroke intervention, building on the recent clinical validation of the TIGERTRIEVER 13 DISTALS device for small vessel occlusions.

The takeaway

The FDA clearance and successful initial U.S. cases of the TIGERTRIEVER 25 demonstrate Rapid Medical's commitment to developing innovative endovascular devices that can improve outcomes for the most challenging acute ischemic stroke cases, where restoring blood flow quickly is critical for minimizing long-term patient disability.